Effect of training the breathing muscles on the ability to exercise in people with non-cystic fibrosis bronchiectasis

Overview

About this study

The objective of this study is to investigate whether a home-based, digitally delivered specific breathing and respiratory muscle training program improves exercise capacity, pulmonary and respiratory muscle function, and clinical status in patients with clinically stable non-CFB

Its aim is to determine the effect of a novel home-based, 8-week, and health-coach supported breathing and respiratory muscle training-based pulmonary rehabilitation program on: a) six-minute walk test distance and peak oxygen consumption; b) pulmonary function; c) ultrasound-derived diaphragm size; d) maximal inspiratory and expiratory muscle strength; and e) subjective measures of symptoms and health-related quality-of-life (HRQoL) in non-CFB patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • 21-80 years of age.
  • Mayo Clinic patient with confirmed diagnosis of Non-Cystic Fibrosis Bronchiectasis (non-CFB):   
    • Non-CFB as confirmed by clinical history, including cough, shortness of breath, exertional dyspnea, pulmonary function tests, and high-resolution computed tomography. Patients will be considered clinically stable if there is no evidence of an exacerbation or change(s) in medical therapy in the previous three weeks.
  • Able and willing to provide informed consent to participate in the study.

Exclusion Criteria:

  • Pregnancy.
  • Presence of significant coexisting disease, neurological conditions, and/or orthopedic complications that affect ability to undertake exercise.
  • Presence of advanced heart failure.
  • Use of antibiotics with the exception of chronic macrolide (azithromycin), antibiotic therapy for MAC/NTM, or chronic inhaled antibiotic use.
  • Acute exacerbation(s) within 3-weeks prior to study commencement.
  • Participation within a pulmonary rehabilitation program within 6-months prior to study commencement.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/14/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Bryan Taylor, Ph.D.

Open for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available